Our Leadership Team
John McKendry is a senior healthcare executive with over 20 years of experience in the biopharmaceutical, medtech and healthtech industries. John is an accomplished business leader and has held leadership positions in Canada and across 15 different countries in Asia-Pacific. John has a deep knowledge of the pharmaceutical industry based on 19 years with Pfizer Inc, including senior commercial leadership roles such as Country Manager and Regional Vice-President across developed and emerging markets.
Prior to joining KYE, John led a global growth-stage medical supplies company and he was the President/Founder of Lateral Line Consulting in Singapore – an independent advisory firm focused on assisting the growth and commercial development of seed-stage healthtech startups in Southeast Asia. Throughout his international career in the private sector, John has built high performing teams to address areas of unmet medical need with a focus on driving growth, profitability, organizational culture and operational excellence.
VP, Scientific Affairs and Compliance
Eryn has a BSc (Applied Biology/Biotechnology), MSc (Human Physiology) and over 25 years of Canadian and global (US/EU) regulatory affairs, medical affairs, and compliance experience. She has extensive experience at several multinational companies (AstraZeneca, Boehringer Ingelheim, Serono) leading to progressive leadership roles growing regulatory, medical, and compliance departmental functions within smaller organizations (Oryx Pharmaceuticals, Sunovion Pharmaceuticals, Verity Pharmaceuticals). She has led numerous regulatory filings and has clinically supported several successful launches (e.g., ANGIOMAX, CUBICIN, APTIOM, LATUDA, IVOZFO) in a wide array of therapeutic areas.
KYE has been founded on an entrepreneurial spirit that optimizes our team’s strengths and brings unique value to our partners, Canadian health care professionals, and most importantly, our patients. From registration to commercialization, the KYE team creatively addresses the challenges of the Canadian pharmaceutical environment to bring important new medicines to our market as quickly and economically as possible.